SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing a surge in trading volume and social media interest as retail investors rally behind a 'Save Wendy's' campaign, targeting the stock's significant short interest for a potential squeeze. Community members are actively sharing takeover rumors, comparing the setup to previous meme stock rallies, and debating the company's long-term value alongside its dividend yield.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense debate as it hits new 52-week lows, with bulls highlighting the Zeta Global partnership and strong defense contracts as indicators of long-term value, while bears point to persistent short-term downward momentum and concerns over high valuation multiples. Investors are actively monitoring key support levels near $100-$106, debating whether this is a structural distribution phase or a deep-value buying opportunity for long-term holders.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid significant investor volatility, fueled by persistent community concerns over share dilution and the stock's decoupling from Bitcoins price action. Investors are actively debating whether the current pullback to long-term support levels represents a generational buying opportunity or the beginning of a deeper structural decline.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is experiencing significant volatility as market participants debate whether recent price declines represent a fundamental shift or a temporary correction linked to broader economic uncertainty. Community discussions are heavily divided between long-term investors citing industrial shortages and physical accumulation as a floor, and traders expressing frustration over the asset's inability to sustain gains despite geopolitical headlines.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is facing extreme volatility as investors weigh a strong revenue beat and multi-billion dollar partnerships against concerns regarding shrinking margins and upcoming insider share lockup expirations. The community remains deeply divided, with some betting on a rapid recovery fueled by AI hardware demand while others anticipate a sharp correction as they scrutinize the stock's valuation and potential selling pressure.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is facing intense selling pressure as investors rotate out of gold, driven by concerns that persistent inflation and a strong dollar will force the Federal Reserve to maintain higher interest rates. The community is sharply divided, with bulls viewing the drop as a structural buying opportunity near key support levels, while bears are aggressively shorting the ETF, anticipating further downside as gold's safe-haven appeal wanes.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following the announcement of a strategic agreement with Fit Energy to supply up to 380MW of clean, on-site power for AI data centers, with an immediate deposit for the first 30MW. While the community is debating the credibility of the partner and the structure of the deal, many bulls are focused on the validation of FCEL's utility-scale tech within the high-demand data center power sector.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is surging as investors react to high-profile executive orders prioritizing quantum technology, with community sentiment boosted by the CEO's direct participation in White House policy discussions. Traders are actively debating whether this momentum will trigger a sustained breakout, focusing heavily on potential institutional index inclusion and upcoming technical product updates.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is experiencing a significant surge following an agreement with Renew Home and Tesla to develop a large-scale virtual power plant, which the community sees as a major catalyst for grid infrastructure and AI-driven energy demand. Investors are actively discussing the stock's high short interest as a potential tailwind for further upward momentum and price discovery.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci Corp is gaining significant attention due to positive clinical updates on its antibody candidate for hair loss and a fresh injection of capital from major healthcare investors. The community is actively debating the potential for a short squeeze given the stock's high short interest and the strategic participation of industry heavyweights like Eli Lilly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.read more...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Misses Expectations By $3.04 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $16.00 by Analysts at Needham & Company LLC

Needham & Company LLC dropped their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Wednesday...

BioCryst Pharmaceuticals Q1 Earnings Call Highlights

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described as a strong start to 2026, driven by continued growth of hereditary angioedema (HAE) therapy ORLADEYO and progress across its development pipeline, while also flagging a manufacturing issue that will delay initial fulfillment...

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -150.00% and +0.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday

BioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock...

Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Phocas Financial Corp. acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The...

SG Americas Securities LLC Sells 102,210 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

SG Americas Securities LLC lessened its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 44.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC...

Aberdeen Group plc Buys Shares of 913,593 BioCryst Pharmaceuticals, Inc. $BCRX

Aberdeen Group plc acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.61
Prev Close	$9.31
Open	$9.42
Dividend Yield	0.00%
50-Day Moving Average	$8.89
Beta	0.96
Avg. Volume	5.09M
PE Ratio	-5.24

52-Week High	$10.32
52-Week Low	$6.00
Market Capitalization	$2.37B
EPS (Annual)	$1.21
Price to Book	-4.27
Revenue Per Employee	$2.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRXBiocryst Pharmaceuticals Inc.

Latest BCRX News